GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » Beneish M-Score
中文

Incyte (WBO:INCY) Beneish M-Score

: -2.21 (As of Today)
View and export this data going back to 2017. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.21 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Incyte's Beneish M-Score or its related term are showing as below:

WBO:INCY' s Beneish M-Score Range Over the Past 10 Years
Min: -3.03   Med: -2.21   Max: -1.47
Current: -2.21

During the past 13 years, the highest Beneish M-Score of Incyte was -1.47. The lowest was -3.03. And the median was -2.21.


Incyte Beneish M-Score Historical Data

The historical data trend for Incyte's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.92 -2.21 -1.94 -3.03 -2.21

Incyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.03 -2.68 -2.88 -2.51 -2.21

Competitive Comparison

For the Biotechnology subindustry, Incyte's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Incyte's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Incyte's Beneish M-Score falls into.



Incyte Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Incyte for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0571+0.528 * 1.0085+0.404 * 1.1918+0.892 * 1.0595+0.115 * 0.8445
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0629+4.679 * 0.01315-0.327 * 0.921
=-2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was €682 Mil.
Revenue was 929.234 + 861.126 + 881.105 + 755.301 = €3,427 Mil.
Gross Profit was 865.227 + 804.813 + 818.064 + 702.249 = €3,190 Mil.
Total Current Assets was €4,260 Mil.
Total Assets was €6,219 Mil.
Property, Plant and Equipment(Net PPE) was €713 Mil.
Depreciation, Depletion and Amortization(DDA) was €77 Mil.
Selling, General, & Admin. Expense(SGA) was €1,077 Mil.
Total Current Liabilities was €1,137 Mil.
Long-Term Debt & Capital Lease Obligation was €27 Mil.
Net Income was 184.389 + 160.479 + 187.875 + 20.271 = €553 Mil.
Non Operating Income was 17.419 + -24.576 + 30.862 + -10.754 = €13 Mil.
Cash Flow from Operations was 135.467 + 138.521 + 282.923 + -98.633 = €458 Mil.
Total Receivables was €609 Mil.
Revenue was 874.805 + 831.536 + 862.182 + 665.777 = €3,234 Mil.
Gross Profit was 818.92 + 776.39 + 814.314 + 627.097 = €3,037 Mil.
Total Current Assets was €3,864 Mil.
Total Assets was €5,514 Mil.
Property, Plant and Equipment(Net PPE) was €723 Mil.
Depreciation, Depletion and Amortization(DDA) was €65 Mil.
Selling, General, & Admin. Expense(SGA) was €957 Mil.
Total Current Liabilities was €1,092 Mil.
Long-Term Debt & Capital Lease Obligation was €28 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(681.842 / 3426.766) / (608.766 / 3234.3)
=0.198975 / 0.188222
=1.0571

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3036.721 / 3234.3) / (3190.353 / 3426.766)
=0.938911 / 0.93101
=1.0085

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4259.834 + 712.553) / 6219.192) / (1 - (3863.65 + 722.734) / 5513.889)
=0.200477 / 0.168212
=1.1918

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3426.766 / 3234.3
=1.0595

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(64.599 / (64.599 + 722.734)) / (76.675 / (76.675 + 712.553))
=0.082048 / 0.097152
=0.8445

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1077.338 / 3426.766) / (956.627 / 3234.3)
=0.314389 / 0.295776
=1.0629

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((26.742 + 1137.428) / 6219.192) / ((28.398 + 1092.281) / 5513.889)
=0.18719 / 0.203247
=0.921

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(553.014 - 12.951 - 458.278) / 6219.192
=0.01315

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Incyte has a M-score of -2.23 suggests that the company is unlikely to be a manipulator.


Incyte (WBO:INCY) Business Description

Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (WBO:INCY) Headlines

From GuruFocus

Q2 2023 Incyte Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Incyte Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Incyte Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Incyte Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Incyte Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024